Integrated Analysis of OX40/OX40L Genetic Variants and Circulating Soluble Immune Checkpoint Markers in Laryngeal Cancer Recurrence

Abstract

Objective: Laryngeal cancer is an aggressive malignancy in which immune regulatory mechanisms play a critical role in tumor progression and recurrence. The OX40/OX40L axis, a member of the tumor necrosis factor superfamily, has been implicated in immune modulation; however, its genetic and soluble profiles in laryngeal cancer remain insufficiently characterized. Beyond cancer susceptibility, the clinical relevance of OX40/OX40L alterations in recurrence biology remains poorly understood. Materials and Methods: In this study, we investigated the distribution of OX40 rs17568 and OX40L rs1234313 polymorphisms and evaluated their association with serum soluble OX40 (sOX40) and OX40L (sOX40L) levels in 80 patients with laryngeal cancer and 111 healthy controls. Genotyping was performed using polymerase chain reaction-restriction fragment length polymorphism (PCR–RFLP), and soluble protein levels were quantified by enzyme-linked immunosorbent assay (ELISA). Results: No significant differences in serum sOX40 or sOX40L levels were observed between patients and controls. While OX40 rs17568 genotype distributions were comparable between groups, a significant difference was detected for OX40L rs1234313, with homozygous genotypes (AA and GG) being more frequent in laryngeal cancer patients (p=0.007). Although genotype distributions were not associated with clinicopathological parameters, circulating sOX40 levels were significantly higher in patients with disease recurrence than in those without recurrence (p=0.008). Conclusion: The findings suggest that alterations in the OX40/OX40L axis may be associated with immune dysregulation during disease progression rather than cancer initiation in laryngeal cancer. Particularly, elevated circulating sOX40 levels were associated with disease recurrence. Given the cross-sectional and exploratory nature of the study, these findings should be interpreted with caution and require validation in larger prospective cohorts.

Keywords

• Laryngeal cancer
• OX40
• OX40L
• genetic polymorphism
• recurrence

References

1. Liberale C, Soloperto D, Marchioni A, Monzani D, Sacchetto L. Updates on larynx cancer: risk factors and oncogenesis. Int J Mol Sci 2023 24(16): 12913. google scholar
2. Bodd MH, McCammon SD. Laryngeal cancer and the end of life (as we know it). Otolaryngol Clin North Am 2023 56(2): 403-12. google scholar
3. Nishimura G, Takahashi H, Sano D, Arai Y, Hatano T, Kitani Y, et al. Risk factors of secondary cancer in laryngeal, oropharyngeal, or hypopharyngeal cancer after definitive therapy. Int J Clin Oncol 2024 29(2): 103-14. google scholar
4. Bassani S, Lee YK, Campagnari V, Eccher A, Monzani D, Nocini R, et al. From hype to reality: a narrative review on the promising role of artificial intelligence in larynx cancer detection and transoral microsurgery. Crit Rev Oncog 2023 28(3): 21-4. google scholar
5. Gonzalez-Pons M, Cruz-Correa M. Colorectal cancer biomarkers: where are we now? Biomed Res Int 2015 2015: 149014. google scholar
6. Suzuki HI, Katsura A, Matsuyama H, Miyazono K. MicroRNA regulons in tumor microenvironment. Oncogene 2015 34(24): 3085-94. google scholar
7. Yu YR, Ho PC. Sculpting tumor microenvironment with immune system: from immunometabolism to immunoediting. Clin Exp Immunol 2019 197(2): 153-60. google scholar
8. Dadas O, Ertay A, Cragg MS. Delivering co-stimulatory tumor necrosis factor receptor agonism for cancer immunotherapy: past, current and future perspectives. Front Immunol 2023 14: 1147467. google scholar

9. An J, Ding S, Li S, Sun L, Chang X, Huang Z, et al. Enhancement of the soluble form of OX40 and OX40L costimulatory molecules but reduction of the membrane form in type 1 diabetes (T1D). J Immunol Res 2019 2019: 1780567. google scholar
10. Jahromi AS, Erfanian S, Roustazadeh A. Association of OX40L gene polymorphism with multiple sclerosis in Iranians. Heliyon 2024 10(6): e27304. google scholar
11. Jahromi AS, Shojaei M, Erfanian S, Maalhagh M, Ghobadifar MA. Lack of Association between OX40L gene polymorphism rs3850641 and the risk of premature myocardial infarction in Iranian population. Int J Pharm Res Allied Sci 2016 5(2): 528-36. google scholar
12. Bell RB, Leidner RS, Crittenden MR, Curti BD, Feng Z, Montler R, et al. OX40 signaling in head and neck squamous cell carcinoma: overcoming immunosuppression in the tumor microenvironment. Oral Oncol 2016 52: 1-10. google scholar
13. Bulliard Y, Jolicoeur R, Zhang J, Dranoff G, Wilson NS, Brogdon JL. OX40 engagement depletes intratumoral Tregs via activating FcgammaRs, leading to antitumor efficacy. Immunol Cell Biol 2014 92(6): 475-80. google scholar
14. Rancoule C, Vallard A, Espenel S, Guy JB, Xia Y, El Meddeb Hamrouni A, et al. Immunotherapy in head and neck cancer: Harnessing profit on a system disruption. Oral Oncol 2016 62: 153-62. google scholar
15. Matsuda K. PCR-based detection methods for single-nucleotide polymorphism or mutation: Real-Time PCR and its substantial contribution toward technological refinement. Adv Clin Chem 2017 80: 45-72. google scholar
16. Wang X, Luan Y, Zhang C. A meta-analysis on correlations of OX40L variants with atherosclerotic disorders. J Cell Biochem 2019 120(6): 9624-30. google scholar
17. Fu Y, Lin Q, Zhang ZR. Association of TNFSF4 polymorphisms with systemic lupus erythematosus: a meta-analysis. Adv Rheumatol 2021 61: 59. google scholar
18. Bilen O, Verim L, Tosun C, Yuksel O, Sever U, Sonmez D, et al. Relationship between bladder cancer and polymorphisms of OX40 (rs17568) and OX40L (rs1234313) genes in a Turkish population. Biotechnol Biotechnol Equip 2023 37(1): 2245923. google scholar
19. Liu S, Xu Z. A meta-analysis on the association between TNFSF4 polymorphisms (rs3861950 T\>C and rs1234313 A\>G) and susceptibility to coronary artery disease. Front Physiol 2020 11: 539288. google scholar
20. Weiguang Y, Dalin L, Lidan X, Yonggang C, Shuang C, Yanhong L, et al. Association of OX40L polymorphisms with sporadic breast cancer in northeast Chinese Han population. PLoS One 2012 7(8): e41277. google scholar
21. Faghih Z, Taherifard E, Daneshmand A, Talei A, Erfani N. OX40 genetic variations in patients with breast cancer: a case-control study. Br J Biomed Sci 2021 78(1): 44-46. google scholar
22. Faghih Z, Abtahi S, Khademi B, Nikfarjam F, Erfani N. Association of OX40 gene polymorphisms (rs17568G/A and rs229811A/C) with head and neck squamous cell carcinoma. Mol Biol Rep 2019 46(3): 2609-16. google scholar
23. Erfanian S, Rahmanian F, Jahromi AS, Hojjat-Farsangi M. Non-association between rs17568 OX40 Gene Polymorphism and Type-2 Diabetes Mellitus, West-south of Iran. J Int Transl Med 2020 8(1): 19-22. google scholar
24. Miller JE, Veturi Y, Ritchie MD. Innovative strategies for annotating the "relationSNP" between variants and molecular phenotypes. BioData Mining 2019 12(1): 1-22. google scholar
25. Deng J, Zhao S, Zhang X, Jia K, Wang H, Zhou C, et al. OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer. Onco Targets Ther 2019 12: 7347-53. google scholar
26. Zaini J, Andarini S, Tahara M, Saijo Y, Ishii N, Kawakami K, et al. OX40 ligand expressed by DCs costimulates NKT and CD4+ Th cell antitumor immunity in mice. J Clin Invest 2007 117(11): 3330-38. google scholar
27. Ria M, Eriksson P, Boquist S, Ericsson CG, Hamsten A, Lagercrantz J. Human genetic evidence that OX40 is implicated in myocardial infarction. Biochem Biophys Res Commun 2006 339(3): 1001-06. google scholar
28. Souza HS, Elia CC, Spencer J, MacDonald TT. Expression of lymphocyte-endothelial receptor-ligand pairs, alpha4beta7/MAdCAM-1 and OX40/OX40 ligand in the colon and jejunum of patients with inflammatory bowel disease. Gut 1999 45(6): 856-63. google scholar
29. Yoshioka T, Nakajima A, Akiba H, Ishiwata T, Asano G, Yoshino S, et al. Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis. Eur J Immunol 2000 30(10): 2815-23. google scholar
30. Olofsson PS, Söderström LA, Wågsäter D, Sheikine Y, Ocaya P, Lang FÖ, et al. CD137 is expressed in human atherosclerosis and promotes development of plaque inflammation in hypercholesterolemic mice. Circulation 2008 117(10): 1292-1301. google scholar
31. Chen Y, Zhang L, Huang H, Liu R, Li X, Qiang O, et al. Association of OX40 and OX40L gene polymorphisms with acute coronary syndrome in a Han Chinese population. DNA Cell Biol 2011 30(8): 597-602. google scholar
32. Yue LY, Xu Y, Tao B, He CS. Association of TNFSF4 gene polymorphisms and plasma TNFSF4 level with risk of systemic lupus erythematosus in a Chinese population. Immunol Invest 2022 51(2): 316-30. google scholar
33. Huang Q, Yang QD, Tan XL, Feng J, Tang T, Xia J, et al. Absence of association between atherosclerotic cerebral infarction and TNFSF4/TNFRSF4 single nucleotide polymorphisms rs1234313, rs1234314 and rs17568 in a Chinese population. J Int Med Res 2014 42(2): 436-43. google scholar
34. Jiang Y, Liu X, Du Y, Zhou S. rs1234313 and rs45454293 are risk factors of cerebral arterial thrombosis, large artery atherosclerosis, and carotid plaque in the Han Chinese population: a case-control study. BMC Neurol 2019 19(1): 31. google scholar
35. Lima CAC, Martins MR, Dos Santos RL, da Silva LM, Da Silva JPA, Forones NM, et al. Soluble levels of 4-1BB (CD137) and OX40 (CD134) are associated with cancer progression in gastric adenocarcinoma. J Surg Oncol 2024 130(4): 734-40. google scholar
36. Lima CAC, Martins MR, Dos Santos RL, da Silva LM, Silva JPA, Torres LC, et al. High soluble OX40 levels correlate with metastatic gastric cancer. J Surg Oncol 2022 126(1): 139-43. google scholar
37. Zor DS, Hakan MT, Özgür E, Horozoglu C, Yörüker EE, Kulle CB, et al. Plasma levels of kynurenine, soluble OX40 and mir-138-5p are associated with tumor-infiltrating lymphocytes in colorectal cancer: an exploratory study. Anticancer Res 2023 43(7): 3281-88. google scholar
38. Sawada R, Arai Y, Sagawa Y, Nagata Y, Nishimura T, Noguchi M, et al. High blood levels of soluble OX40 (CD134), an immune costimulatory molecule, indicate reduced survival in patients with advanced colorectal cancer. Oncol Rep 2019 42(5): 2057-64. google scholar
39. Zhou X, Wang X, Gu Y, Chen L, Shen Y, Tian J, et al. Clinical significance of OX40 and OX40 ligand in the peripheral blood of patients with myasthenia gravis. J Immunol Res 2022 2022: 4337399. google scholar